Latest Insider Transactions at Agios Pharmaceuticals, Inc. (AGIO)
This section provides a real-time view of insider transactions for Agios Pharmaceuticals, Inc. (AGIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AGIOS PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AGIOS PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
1,400
-7.37%
|
$56,000
$40.0 P/Share
|
|
Jul 10
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+6.86%
|
$25,200
$18.09 P/Share
|
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,914
-8.24%
|
$452,732
$38.34 P/Share
|
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,914
+14.0%
|
$297,850
$25.01 P/Share
|
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,091
-6.26%
|
$139,094
$34.17 P/Share
|
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,374
+11.36%
|
-
|
|
Jun 24
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,909
-4.86%
|
$95,997
$33.54 P/Share
|
|
Jun 24
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+9.11%
|
-
|
|
Jun 24
2025
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,799
-8.9%
|
$92,367
$33.54 P/Share
|
|
Jun 24
2025
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+16.02%
|
-
|
|
Jun 24
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,700
-7.93%
|
$617,100
$33.54 P/Share
|
|
Jun 24
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,277
+13.77%
|
-
|
|
Jun 24
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,770
-9.59%
|
$91,410
$33.54 P/Share
|
|
Jun 24
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+17.2%
|
-
|
|
Jun 24
2025
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,780
-5.59%
|
$58,740
$33.54 P/Share
|
|
Jun 24
2025
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+15.86%
|
-
|
|
Jun 20
2025
|
Jeffrey D Capello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+25.88%
|
-
|
|
Jun 20
2025
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+17.33%
|
-
|
|
Jun 20
2025
|
Catherine E. Owen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+25.88%
|
-
|
|
Jun 20
2025
|
Maykin Ho Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+11.07%
|
-
|
|
Jun 20
2025
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+1.38%
|
-
|
|
Jun 20
2025
|
Kaye I Foster Cheek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+22.11%
|
-
|
|
Jun 20
2025
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+17.33%
|
-
|
|
Jun 20
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,120
+10.75%
|
-
|
|
Jun 13
2025
|
Catherine E. Owen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,977
+33.34%
|
-
|
|
Jun 13
2025
|
Jeffrey D Capello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,977
+33.34%
|
-
|
|
Apr 10
2025
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
7,497
-4.78%
|
$187,425
$25.9 P/Share
|
|
Apr 08
2025
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,933
+9.23%
|
-
|
|
Mar 03
2025
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,275
-4.38%
|
$79,625
$35.54 P/Share
|
|
Mar 03
2025
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,005
-5.73%
|
$140,175
$35.54 P/Share
|
|
Mar 03
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,947
-6.73%
|
$453,145
$35.54 P/Share
|
|
Mar 03
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,681
-6.84%
|
$58,835
$35.54 P/Share
|
|
Mar 03
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,655
-6.39%
|
$57,925
$35.54 P/Share
|
|
Mar 03
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,005
-2.57%
|
$140,175
$35.54 P/Share
|
|
Mar 01
2025
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,667
+12.63%
|
-
|
|
Mar 01
2025
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+16.17%
|
-
|
|
Mar 01
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,500
+11.99%
|
-
|
|
Mar 01
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,667
+18.74%
|
-
|
|
Mar 01
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,577
+17.46%
|
-
|
|
Mar 01
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,500
+7.96%
|
-
|
|
Feb 05
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,272
-29.47%
|
$77,248
$34.39 P/Share
|
|
Feb 01
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,896
+47.22%
|
-
|
|
Jan 06
2025
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,804
-12.92%
|
$89,728
$32.18 P/Share
|
|
Jan 03
2025
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,476
+28.08%
|
-
|
|
Dec 11
2024
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.28%
|
$9,200
$46.28 P/Share
|
|
Dec 11
2024
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.26%
|
$3,600
$18.09 P/Share
|
|
Nov 08
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
772
-48.71%
|
$43,232
$56.09 P/Share
|
|
Nov 08
2024
|
Rahul D. Ballal Director |
SELL
Open market or private sale
|
Direct |
10,000
-23.28%
|
$580,000
$58.34 P/Share
|
|
Nov 08
2024
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.72%
|
$250,000
$25.99 P/Share
|
|
Nov 07
2024
|
Rahul D. Ballal Director |
SELL
Open market or private sale
|
Direct |
10,000
-32.07%
|
$530,000
$53.87 P/Share
|